Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine nerve block for PIP joints in RA
NCT04130178Completed
- Sponsor
- Sohag University
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection in rheumatoid arthritis (RA) (2 arms), sponsored by Sohag University. Primary endpoints: VAS at 8 weeks and EULAR-OMERACT at 8 weeks. Started Oct 2019; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04130178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130178.